Corcept Therapeutics Inc (CORT) Stock AnalysisCORTCorcept Therapeutics Inc

Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. It is also conducting advanced clinical trials in patients with solid tumors, Amyotrophic Lateral Sclerosis (ALS) and liver disease. It operates through the discovery, development and commercialization of the pharmaceutical products segment. It sells Korlym and a generic version of Korlym in the United States using sales representatives to call on physicians caring for patients with hypercortisolism (Cushing’s syndrome). The Company's portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. It sells and distributes Lifyorli in the United States. It is developing its proprietary, selective cortisol modulator, relacorilant, as a treatment for patients with hypercortisolism. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Corcept Therapeutics Inc is a good buy right now due to its strong recent performance and positive catalysts. The current price is $121.19, with a 1-year change of +69.43% and a year-to-date change of +217.25%. The RSI is at 64.85, indicating bullish momentum. However, there is a risk with insider selling increasing by 271.06% over the last month, which could signal caution among insiders.

5 analysts cover CORT: 3 rate it Buy, 0 Hold and 2 Sell. The average price target is 91.00.